Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-02-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see how effective the combination of the two chemotherapy
drugs (carboplatin and nab-paclitaxel) are when added to a third drug, pembrolizumab.
Pembrolizumab is an investigational (experimental) drug that works by reinvigorating the
immune system, allowing it to target and destroy cancer cells. Pembrolizumab is experimental
because it is not approved by the Food and Drug Administration (FDA) for this type of breast
cancer treatment.